Johnson & Johnson (JNJ) Non-Current Debt (2009 - 2026)
Johnson & Johnson (JNJ) posted Non-Current Debt of $37.5 billion for Q1 2026, down 4.85% sequentially from $39.4 billion in Q4 2025, and down 2.16% YoY from $38.4 billion in Q1 2025.
Johnson & Johnson (JNJ) Non-Current Debt (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Non-Current Debt data on file, last reported at $37.5 billion in Q1 2026.
- Quarterly Non-Current Debt fell 2.16% year-over-year to $37.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.5 billion (down 2.16% YoY) and the FY2025 annual result came in at $39.4 billion, up 28.67% from the prior year.
- Non-Current Debt retreated to $37.5 billion in Q1 2026 per JNJ's latest filing, from $39.4 billion in the prior quarter.
- The five-year high for Non-Current Debt was $39.4 billion in Q4 2025, with the low at $25.1 billion in Q1 2024.
- Average Non-Current Debt over 5 years is $31.9 billion, with a median of $31.0 billion recorded in 2024.
- Year-over-year, Non-Current Debt fell 28.19% in 2024 and surged 52.92% in 2025.
- Johnson & Johnson's Non-Current Debt stood at $27.6 billion in 2022, then fell by 6.24% to $25.9 billion in 2023, then advanced by 18.43% to $30.7 billion in 2024, then increased by 28.67% to $39.4 billion in 2025, then decreased by 4.85% to $37.5 billion in 2026.
- Business Quant data shows JNJ's Non-Current Debt at $37.5 billion in Q1 2026, $39.4 billion in Q4 2025, and $39.4 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 39.37 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 37.53 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 64.53 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -24.45 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 46.67 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 51.89 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 20.86 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 60.57 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 37.53 Bn |
| Dec 28, 2025 | 39.44 Bn |
| Sep 28, 2025 | 39.41 Bn |
| Jun 29, 2025 | 39.24 Bn |
| Mar 30, 2025 | 38.36 Bn |
| Dec 29, 2024 | 30.65 Bn |
| Sep 29, 2024 | 31.29 Bn |
| Jun 30, 2024 | 31.64 Bn |
| Mar 31, 2024 | 25.08 Bn |
| Dec 31, 2023 | 25.88 Bn |
| Oct 1, 2023 | 26.05 Bn |
| Jul 2, 2023 | 33.90 Bn |
| Apr 2, 2023 | 34.93 Bn |
| Jan 1, 2023 | 26.89 Bn |
| Oct 2, 2022 | 27.60 Bn |
| Jul 3, 2022 | 28.29 Bn |
| Apr 3, 2022 | 28.85 Bn |
| Jan 2, 2022 | 29.99 Bn |
| Oct 3, 2021 | 30.13 Bn |
| Jul 4, 2021 | 30.31 Bn |